Posted on February 9, 2017 by Sitemaster
According to a recently published article in The Prostate, researchers at the University of Minnesota have developed a new type of drug that they believe may have high therapeutic potential in the treatment of castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development | Tagged: CRPC, development, drug, Minnelide, triptolide | 5 Comments »
Posted on January 26, 2017 by Sitemaster
So the other morning your sitemaster learned that a relatively new FirstWord Therapy Report had come out that dealt with future use of biopharmaceuticals in the treatment of progressive and advanced prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: analysis, development, drug, information, new, ongoing | 4 Comments »
Posted on July 14, 2016 by Sitemaster
Readers with an interest in how we got to today’s clinical trials processes for evaluating new drugs for the treatment of prostate cancer and other diseases might be surprised by what’s in an article in this week’s New England Journal of Medicine. … READ MORE …
Filed under: Drugs in development | Tagged: development, drug, marketing, regulation, trials | 2 Comments »
Posted on April 14, 2016 by Sitemaster
For readers who are interested in the processes and the speed with which potential new cancer drugs can be brought to market here in the USA (and other places around the world too), there in an important article in this week’s New England Journal of Medicine. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: development, drug, effectiveness, new, safety, speed | Leave a comment »
Posted on March 4, 2016 by Sitemaster
Many readers of this blog will be aware of the development of immunotherapies like sipuleucel-T (Provenge), CAR-T for the treatment of leukemias, and checkpoint inhibitors in the treatment of some forms of solid tumor (lung cancers, melanoma). … READ MORE …
Filed under: Drugs in development | Tagged: development, drug, immunotherapy, neoantigen | Leave a comment »
Posted on October 13, 2015 by Sitemaster
According to an hypothesis just published by a group of researchers at the Dana-Farber Cancer Institute in Boston, they have identified “a new epigenetic program occurring as you transition from normal to tumor cells” in the development of prostate cancer. … READ MORE …
Filed under: Risk | Tagged: cancer, development, epigenetics, gene, programming, prostate | Leave a comment »
Posted on August 1, 2013 by Sitemaster
There is an excellent opinion piece in this this week’s New England Journal of Medicine that addresses the need for greater focus on patient-reported outcomes in the development of drugs for the treatment of cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: development, drug, outcomes, patient-reported | 7 Comments »